KMT2D upregulates SMG1 via histone methylation to antagonize mTOR and reinforce DLBCL ferroptosis
Journal of Leukocyte Biology · 2025
DOI: 10.1093/jleuko/qiaf092 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Leukocyte Biology, 2025. Verfasst von Yongcheng Sun und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital of Ningbo University, No. 59 Liuting Street, Haishu District, Ningbo 315010, China. Hauptthemen laut MEDLINE: Ferroptosis, Lymphoma, Large B-Cell, Diffuse, Histones, TOR Serine-Threonine Kinases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Ningbo Science and Technology Bureau.
Abstract (Originalsprache)
Diffuse large B-cell lymphoma (DLBCL) is highly heterogeneous and prone to epigenetic mutations. Non-apoptotic cell death pathways, especially ferroptosis, have become an emerging direction for cancer treatment. This project was designed to probe into the potential of histone-lysine N-methyltransferase 2D (KMT2D) in modulating DLBCL ferroptosis through epigenetic mechanisms. We employed quantitative real-time polymerase chain reaction (qRT-PCR) and western blot (WB) to detect the expression level of KMT2D, CCK-8 assay to measure cell viability, flow cytometry to assess cell cycle and apoptosis, and fluorescent probes to analyze lipid reactive oxygen species levels. 4-hydroxynonaldehyde (4-HNE) and malondialdehyde were detected by WB and corresponding kits to determine the degree of intracellular ferroptosis. The level of H3K4Me1 was determined by using WB and immunofluorescence. Furthermore, we verified the transcriptional regulatory relationship between KMT2D and SMG1 through bioinformatics analysis, chromatin immunoprecipitation assay. We also applied WB to assess the activation of the AKT-mTOR pathway. Finally, the in vitro experimental results were validated by qRT-PCR, WB, immunohistochemistry, and fluorescent probe detection in a xenograft tumor model constructed in BALB/c nude mice. Overexpression of KMT2D considerably repressed the malignant behavior of DLBCL and triggered ferroptosis in cells. KMT2D was able to bind directly to the promoter region of the SMG1 gene and induce the transcriptional antagonistic mTOR pathway of SMG1 through H3K4Me1, thereby inducing ferroptosis in DLBCL cells. These findings demonstrate that KMT2D reinforces ferroptosis in DLBCL by antagonizing SMG1-mediated mTOR signaling, identifying it as a novel therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, The First Affiliated Hospital of Ningbo University, No. 59 Liuting Street, Haishu District, Ningbo 315010, China.
ORCID-Profile: Yongcheng Sun
Förderung
- Ningbo Science and Technology Bureau
Zitieren
APA
Sun, Y., Xu, Z., Wang, Z., Zhang, Y., Zhang, P., Sheng, L., Yang, S., & Ouyang, G. (2025). KMT2D upregulates SMG1 via histone methylation to antagonize mTOR and reinforce DLBCL ferroptosis. Journal of Leukocyte Biology. https://doi.org/10.1093/jleuko/qiaf092
Vancouver
Sun Y, Xu Z, Wang Z, Zhang Y, Zhang P, Sheng L, et al. KMT2D upregulates SMG1 via histone methylation to antagonize mTOR and reinforce DLBCL ferroptosis. Journal of Leukocyte Biology. 2025. doi:10.1093/jleuko/qiaf092
BibTeX
@article{Sun2025,
author = {Sun, Yongcheng and Xu, Zhijuan and Wang, Zanzan and Zhang, Yanli and Zhang, Ping and Sheng, Lixia and Yang, Shujun and Ouyang, Guifang},
title = {KMT2D upregulates SMG1 via histone methylation to antagonize mTOR and reinforce DLBCL ferroptosis},
journal = {Journal of Leukocyte Biology},
year = {2025},
doi = {10.1093/jleuko/qiaf092}
}
EUVIMED